Protalix BioTherapeutics (PLX) Hit as EMA CHMP Denies MAA for Taliglucerase Alfa

June 22, 2012 8:44 AM EDT
Protalix BioTherapeutics (AMEX: PLX) shares are lower following news taliglucerase alfa did not get marketing approval from the EMA CHMP.

Shares are down about 14 percent ahead of the bell Friday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Insiders' Blog, Momentum Movers

Add Your Comment